InvestorsHub Logo
Followers 43
Posts 2488
Boards Moderated 0
Alias Born 10/19/2015

Re: georgejjl post# 233398

Thursday, 02/13/2020 11:45:55 AM

Thursday, February 13, 2020 11:45:55 AM

Post# of 464707
No, it doesn't add anywhere near that amount of value.

The current value of the priority review voucher is less than $100 million. In 2015, United Therapeutics sold one for $350 million. In 2018, one sold for $81 million. Congress is trying to make it easier to have access to medicine, especially experimental medicine (i.e. Right to Try Act) and that is driving the value of these review vouchers.

Anavex has 50 million shares outstanding. I'm sure its more but lets use 50 million to be conservative.

At its peak, $350M / 50M shares would be $7/share.

Currently, $80M / 50M shares would be $1.60.

How do you get $15 to $16? Please cite a source that shows the value of these review vouchers is now above $700 million? Thanks!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News